Quantitative Large Scale Proteomics of Lysosomal Storage Disease
Lysosomal storage diseases (LSD) are a group of ~ 50 genetic disorders, which mainly affect children. LSDs are clinically heterogeneous but are frequently dominated by progressive neurologic deterioration. Most patients pass away...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
PTQ-08-01-06872
PROYECTO DIAGNÓSTICO EDLs. DESARROLLO DE UN SISTEMA DE DIAGN...
81K€
Cerrado
BIO2009-07990
DESARROLLO DE TECNICAS DE PROTEOMICA DE SEGUNDA GENERACION P...
358K€
Cerrado
PID2020-115092GB-I00
DESARROLLO DE METODOS PROTEOMICA CUANTITATIVOS PARA APLICACI...
145K€
Cerrado
RARE MAPS
Dynamic proteomic maps of stem cell derived neurons as a mec...
163K€
Cerrado
TRNAMODI
The in vivo roles of tRNA modification
2M€
Cerrado
EQC2021-007086-P
Plataforma de proteómica estructural basada en espectrometrí...
800K€
Cerrado
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
Lysosomal storage diseases (LSD) are a group of ~ 50 genetic disorders, which mainly affect children. LSDs are clinically heterogeneous but are frequently dominated by progressive neurologic deterioration. Most patients pass away after years of lingering illness. In general, the molecular pathogenesis of LSDs is still poorly understood. To gain insight into disease mechanisms the project investigates cellular proteomic alterations sequentially induced by increasing lysosomal storage. In vivo and in vitro models of selected LSDs affecting the nervous system will be investigated. Whole cell proteomes, subcellular fractions and tissues will be analyzed using quantitative large scale mass spectrometry based proteomic techniques employing stable isotope labeling based multiplex quantification approaches (TMT, iTRAQ, SILAC) and tandem mass spectrometry on an Orbitrap Velos mass spectrometer.
Three model systems focusing on glial and neuronal cells will be analyzed: a) in vitro differentiation of NG2 glia to oligodendrocytes under normal or sulfatide accumulating conditions as a model for metachromatic leukodystrophy (MLD); b) in vivo alterations occurring in the course of progressive demyelination in the peripheral nervous system of a mouse model of MLD c) a cell culture model in which consequences of increasing storage of ß-glucosylceramide in neurons will be examined as a model of Gaucher disease.
Using the quantitative data, alterations in protein expression and phosphorylation will be identified, grouped and analyzed for up- and downstream interaction partners as well as biological processes they are involved in. This will be done for various levels of storage to understand the succession and possibly the hierarchy of events. These data will allow describing cellular consequences of lysosomal storage in a so far unprecedented way, will allow generating new working hypotheses, and may provide the basis for the identification of new therapeutic targets.